We are live on
!
Find out more
ACM
AIHC Capital Management Portfolio holdings
AUM
$104M
This Fund
S&P 500
This Quarter
Est. Return
+58.21%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$107M
AUM Growth
–
Cap. Flow
+$93.3M
Cap. Flow
% of AUM
87.48%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
6
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$59M |
| 2 |
Protagonist Therapeutics
PTGX
|
+$15.5M |
| 3 |
ArriVent BioPharma
AVBP
|
+$13.4M |
| 4 |
Cogent Biosciences
COGT
|
+$2.81M |
| 5 |
NBP
NovaBridge Biosciences American Depositary Shares
NBP
|
+$1.83M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
TPW
TOTUOP
XFP
SFG
JRSI
VA
IAP
GAM
AIHC Capital Management's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for AIHC Capital Management, which disclosed 6 positions worth $107M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Revolution Medicines: 900,392 shares worth $71.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- AIHC Capital Management's largest Q4 2025 buy was Revolution Medicines: 900,392 shares worth $71.7M.
- AIHC Capital Management's ten largest holdings make up 100% of its $107M portfolio in Q4 2025.
- AIHC Capital Management disclosed 6 positions in Q4 2025, its first 13F filing on record.
Based on AIHC Capital Management's 13F filing for Q4 2025, filed 5 Feb 2026.